Bio-Path Holdings, Inc. (BPTH) Appoints Tara Sadeghi As Director Of Clinical Operations

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH)("Bio-Path"), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Tara Sadeghi has joined the company as Director of Clinical Operations. Reporting to Dr. Ulrich Mueller, Chief Operating Officer, Ms. Sadeghi will be responsible for all clinical activities surrounding the Company's drug development programs.

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.